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Abstract
Background: Francisella tularensis is a category-A select agent and is responsible for tularemia in humans and animals. The
surface components of F. tularensis that contribute to virulence are not well characterized. An electron-dense capsule has
been postulated to be present around F. tularensis based primarily on electron microscopy, but this specific antigen has not
been isolated or characterized.
Methods and Findings: A capsule-like complex (CLC) was effectively extracted from the cell surface of an F. tularensis live
vaccine strain (LVS) lacking O-antigen with 0.5% phenol after 10 passages in defined medium broth and growth on defined
medium agar for 5 days at 32uCi n7 %C O 2. The large molecular size CLC was extracted by enzyme digestion, ethanol
precipitation, and ultracentrifugation, and consisted of glucose, galactose, mannose, and Proteinase K-resistant protein.
Quantitative reverse transcriptase PCR showed that expression of genes in a putative polysaccharide locus in the LVS
genome (FTL_1432 through FTL_1421) was upregulated when CLC expression was enhanced. Open reading frames
FTL_1423 and FLT_1422, which have homology to genes encoding for glycosyl transferases, were deleted by allelic
exchange, and the resulting mutant after passage in broth (LVSD1423/1422_P10) lacked most or all of the CLC, as
determined by electron microscopy, and CLC isolation and analysis. Complementation of LVSD1423/1422 and subsequent
passage in broth restored CLC expression. LVSD1423/1422_P10 was attenuated in BALB/c mice inoculated intranasally (IN)
and intraperitoneally with greater than 80 times and 270 times the LVS LD50, respectively. Following immunization, mice
challenged IN with over 700 times the LD50 of LVS remained healthy and asymptomatic.
Conclusions: Our results indicated that the CLC may be a glycoprotein, FTL_1422 and -FTL_1423 were involved in CLC
biosynthesis, the CLC contributed to the virulence of F. tularensis LVS, and a CLC-deficient mutant of LVS can protect mice
against challenge with the parent strain.
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Introduction
Francisella tularensis is a Gram-negative coccobacillus, and the
etiologic agent of tularemia in a wide variety of animals and
humans. F. tularensis resides in macrophages, hepatocytes, and a
variety of other cells as a facultative intracellular pathogen, but
may also be found in the blood during infection [1]. Humans may
acquire the agent by handling infected animals, ingesting food or
water containing the pathogen, through bites from arthropod
vectors (e.g. ticks), or by aerosol, which is the route of exposure of
most concern due to intentional release of this agent. The most
pathogenic isolates of F. tularensis are type A1 strains (subspecies
tularensis), which may cause human infection with as few as 10
organisms [2,3], and are associated with 30% mortality in the
absence of antibiotics following pneumonic tularemia [1,4]. Type
B strains (subspecies holarctica) are also highly virulent, but are not
associated with the same level of mortality as subspecies tularensis
[2].
Due to their ease of culture and dispersal, persistence in the
environment, and high virulence, F. tularensis is classified as a
Category-A select agent by the CDC [2]. An approved, licensed
vaccine for tularemia is not currently available. However, a live
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from a type B strain following extensive passage and testing in vitro
and in animals [5]. LVS has been used to protect laboratory
workers from infection with type A strains [6], but is not currently
approved as a vaccine for the general population due to its poor
characterization, potential instability, and questionable safety for
immuno-compromised individuals [7]. Although attenuated in
humans, LVS is antigenically identical to type A strains, and has
been used extensively in research as this strain remains highly
virulent for mice, particularly by the intraperitoneal (IP) and
respiratory routes [8].
Although F. tularensis was first isolated nearly 100 years ago [9],
relatively little is known regarding its surface components that
contribute to virulence. The lipopolysaccharide (LPS) has been
well characterized, and is required for resistance of F. tularensis to
antibody and complement-mediated bactericidal activity and for
virulence [10,11,12,13]. Antibodies to the O-antigen provide
protection to mice challenged with LVS [14,15], but not against
challenge with type A strains [16]. LVS mutants lacking O-antigen
induce some protection against challenge with LVS or type B
strains, but protection against type A challenge is inadequate
[11,12,13,17]. Although individual outer membrane proteins have
not provided protection against challenge of mice with type A
strains [18], a native outer membrane protein preparation did
provide partial protection [19].
An electron-dense surface material resembling a capsule has
been demonstrated around types A and B strains of F. tularensis by
electron microscopy (EM), resulting in the conclusion that these
subspecies may be encapsulated [20,21,22,23]. Furthermore, a
halo-like appearance has been reported around individual F.
tularensis cells within macrophages [24,25], and it has been
hypothesized that once the bacteria are inside the late endo-
some/phagosome compartment, certain components of the
bacterial capsule or membrane are rapidly released leading to
the degradation of the membrane and release of the bacteria into
the cytoplasm [26]. However, these electron dense surface
structures are not always visible, suggesting this capsule-like
complex (CLC) is upregulated under specific environmental/
growth conditions [27]. A carbohydrate-protein-lipid component
distinct from LPS was identified by Hood that is readily removed
under hypertonic conditions [28], and its expression can be
enhanced by repeated subculture in defined medium [27]. This
crude extract from F. tularensis strain SCHU S4 contained
carbohydrate (including mannose, rhamnose, and two unidentified
dideoxy sugars), as well as amino acids, and 2OH 14:0 and 16:0
fatty acids. However, a specific component was neither purified
nor well characterized. Recently, Apicella et al. [29] described an
O-antigen capsular polysaccharide around all F. tularensis type A
and B strains tested. Mutations in genes encoding for O-antigen
glycosyltransferases blocked LPS O-antigen and capsule biosyn-
thesis, but mutations in genes encoding for O-antigen polymerase
or acyltransferase only prevented LPS O-antigen synthesis, not
capsule synthesis. Furthermore, Lindemann et al. [30] identified a
locus in strain SCHU S4 separate from the O-antigen locus [31]
that is required for LPS O-antigen and/or capsule biosynthesis.
Mutations in any of the three genes in this locus resulted in loss of
LPS O-antigen and/or O-antigen capsule and increased serum
sensitivity of SCHU S4. In addition, the mutants were taken up by
human monocyte-derived macrophages more rapidly, but did not
continue to increase their replication after 16 hours. Macrophages
infected with the mutants also undergo early cell death, in contrast
to macrophages infected with SCHU S4. Therefore, the LPS O-
antigen and/or the O-antigen capsule are essential to F. tularensis
persistence in macrophages and replication in the host. The F.
tularensis genes capBC have low-level homology to capBC of the
Bacillus anthracis capBCADE locus, which encodes for proteins that
synthesize the poly-D-glutamic acid capsule [32,33]. Deletion of
capB in both F. tularensis LVS and the highly virulent SCHU S4
strain attenuate the bacteria, which are capable of inducing
protection in mice against challenge with the parent strain
[34,35,36,37]. However, poly-D-glutamic acid has not been found
in any extracts of F. tularensis [36,38], and there is no evidence that
capBC contributes to synthesis of the electron dense CLC.
A genetic locus that may encode for proteins involved in
synthesis and export of a polysaccharide other than LPS has been
identified in the genome sequence of F. tularensis LVS
(NC_007880), and the same genes are present in type A strain
SCHU S4 [32] (NC_006570). This locus contains 12 putative
genes in the LVS genome: FTL_1432 through FTL_1421. We
sought to purify and analyze the electron dense CLC that appears
to be upregulated under specific growth conditions, with emphasis
on the carbohydrate component. Furthermore, to determine if the
above locus is involved in synthesis of the carbohydrate
component of the LVS CLC, two putative genes encoding for
proteins with homology to a galactosyl transferase and a mannosyl
transferase were deleted by allelic exchange. The CLC isolated
appeared to be a glycoprotein and distinct from the O-antigen
capsular polysaccharide. The glycosyl transferase mutant lacked
CLC expression, was attenuated in mice, but provided protection
against subsequent challenge with the parent.
Results
Extraction of CLC
Gentle extraction of LVS with 10% NaCl [28] following growth
on Chocolate agar for several days yielded a carbohydrate that was
distinct from LPS, as determined by gas chromatography/mass
spectrometry (GC/MS). However, the yield of this material was
poor and many other components were present in the extract,
including LPS and a wide variety of proteins.
Cherwonogrodzky [27] reported that daily passage of F.
tularensis LVS in Chamberlain’s defined medium broth (CDMB),
followed by growth on Chamberlain’s defined medium agar
(CDMA), resulted in an increase of the electron dense material
surrounding the bacteria. Therefore, to enhance CLC synthesis
and minimize contamination with LPS, the LVS O-antigen
mutant WbtIG191V [11] was subcultured daily in CDMB for
seventeen days (WbtIG191V_P17), followed by growth at 32uC for 5
days on CDMA in 7% CO2. Parent strain LVS was passed in the
same way for 10 days to obtain LVS_P10. Negative staining EM
confirmed that such passage resulted in an increase in CLC
synthesis around LVS_P10 (Fig. 1A and 1E), and around
WbtIG191V_P17 (Fig. 1G), but very little CLC (arrow) was seen
around LVS that had not been passed in CDMB and cultured at
37uC (Fig. 1F). Similar results were obtained with type A strains
SCHU S4 and TI0902 that were passed in the same way in
CDMB and CDMA (Fig. 1B). In the latter analysis, but also in
others, the CLC around the cell appeared to aggregate and was
more dense than diffuse, possibly due to fixation during EM
(Fig. 1B). After scanning multiple micrographs (.10) of strains
enhanced for expression of CLC (LVS_P10, WbtIG191V_P17,
TI0902 passed 10 times, and passed complemented mutant
LVSD1423/1422_P10) at least 75% of the cells were observed to
make at least as much CLC as shown in Fig. 1. In contrast, no cells
of either of the CLC mutants (LVSD1423/1422_P10 and
WbtIG191V_P17D1423/1422) described below were observed to
have enhanced CLC around them. Western blot analysis of LPS
from exactly the same number of cells of LVS and LVS_P10
Isolation and Mutagenesis of LVS CLC
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(data not shown). Therefore, the enhanced electron dense material
around the passed cells was not LPS.
We also tested the effect of supplementing CDMA with the
carbon sources glycerol, galactose, or glucose to further enhance
CLC synthesis. LVS_P10 colonies grown on 1% glycerol appeared
similar to LVS grown on CDMA. There was substantially less
growth and colony iridescence of bacteria incubated on 1%
galactose. However, colonies grown on 1% glucose (Glc-CDMA)
appeared more mucoid and more iridescent than those on CDMA
alone (data not shown). When the CLC was extracted from 10
plates of WbtIG191V_P17 grown on each carbon source at 32uC for
5 days there was 10% or more CLC recovered from bacteria
grown on Glc-CDMA than on media supplemented with the other
carbon sources, as determined by protein and carbohydrate assays
(data not shown). Therefore, the bacteria were grown on Glc-
CDMA for subsequent extraction of CLC.
When WbtIG191V_P17 was grown on Glc-CDMA as described
above, extracted with 0.5% phenol, and the cells removed by
centrifugation, the extract was thick, frothed easily, and was
slightly yellow in color. Furthermore, this extract became highly
insoluble when the phenol was removed or the material
concentrated. The solubility of the extracted CLC was greatly
improved after ethanol precipitation, digestion with RNase,
DNase, and in particular Proteinase K (which also eliminated
frothing). Following ultracentrifugation and dialysis, further
purification (primarily to remove ribose) was obtained by gel
filtration through Sephacryl S-300 (see Materials and Methods).
Approximately 2.8 mg of purified, LPS-free CLC was obtained
per gram (wet weight) of WbtIG191V_P17 cells grown on
Glc-CDMA.
Physical and chemical characterization of the CLC
Following electrophoresis the extracted CLC appeared as a
large molecular size, heterogeneous smear after staining with
Stains All/silver stain (though distinct bands were apparent as
color initially developed) (Fig. 2B), and by Western blotting with
antiserum to whole cells (Fig. 2C). Although purified LPS was
clearly observed by Western blotting with antibody to O-antigen,
an equivalent amount of F. tularensis LPS was not stained by Stains
All/silver stain (probably due to the presence of only dideoxy
glycoses in the O-antigen), further showing that the CLC was
distinct from LPS. Furthermore, as the source of the CLC was an
O-antigen negative mutant, the high molecular size material in the
CLC could not be LPS. However, there was very little reactivity of
the CLC with the fluorescent stain Pro-Q Emerald (Fig. 2D). The
profile of the crude extract obtained following 0.5% phenol
extraction showed a wide variety of proteins. However, a few low
molecular size proteins were still present in the CLC following
enzyme digestion, as shown by Coomassie Blue staining (Fig. 2A).
The composition of the carbohydrate in the CLC was
determined by GC/MS. Multiple (.10) analyses consistently
indicated that the carbohydrate consisted of the neutral residues
glucose, mannose, and galactose (Fig. 3). Ribose, xylose, or C18:0
fatty acids were occasional but inconsistent contaminants, and if
present were removed by column chromatography. Monosaccha-
ride residues unique to LPS, such as KDO or quinovosamine,
were not present. In addition, galactose is not present in the LPS of
Figure 1. Negative stain electron microscopy of the CLC of F. tularensis. Panels A and E: type B strain LVS_P10 grown at 32uC on Glc-CDMA;
different cultures were examined on different days; Panel B: type A strain TI0902, passed and grown to enhance CLC expression as for LVS. In this and
some other cases the CLC appeared to aggregate, which also occurred following isolation of the CLC; Panel C: glycosyl transferase mutant LVSD1423/
1422_P10; Panel D: complemented strain LVSD1423/1422[1423/1422
+]_P10; Panel F: LVS not passed in defined medium and grown on CDMA at 37uC;
only a small amount of CLC is visible (arrow); Panel G: O-antigen mutant WbtIG191V_P17 grown as for LVS_P10; Panel H: O-antigen and CLC double
mutant WbtIG191V_P17D1423/1422. Strains LVS_P10, WbtIG191V_P17, and type A strain TI0902_P10 have an electron dense layer surrounding their
cells. This layer is missing in mutants LVSD1423/1422_P10 and WbtIG191V_P17D1423/1422, and is restored in complemented strain LVSD1423/
1422[1423/1422
+]_P10]. The bacteria were fixed in glutaraldehyde, and stained with uranyl acetate. Magnification is 20,000 X, and the scale bar is
500 nm.
doi:10.1371/journal.pone.0019003.g001
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distinct from LPS. Purified CLC was readily precipitated by
addition of excess cold ethanol, further supporting that the CLC
was of large molecular size. These collective results indicated that
the CLC on the bacterial surface was a glycoprotein.
Identification of the putative genes responsible for CLC
carbohydrate biosynthesis
BLAST analysis of the F. tularensis LVS genome sequence
identified a 12.5 kb locus containing 12 genes (FTL_1432-
FTL_1421) with homology to genes that encode for proteins
Figure 2. Polyacrylamide gel electrophoresis of CLC extracts. CLC extracts at various stages of purity, or F. tularensis LPS as a control, were
separated by electrophoresis in a 4–12% separating gel, and the components identified by (A), Coomassie Blue for protein; (B), Stains-All/silver stain
for acidic molecules; (C), Western blot with antiserum to LVS whole cells for antigenic components; (D), Pro-Q Emerald stain for carbohydrate. Lanes
for panels A-C: M, molecular size standards; 1, LVS LPS (20 mg); 2, crude CLC prior to enzyme digestion (20 mg); 3, CLC extract following enzyme
digestion (20 mg); 4, purified CLC (20 mg). Lanes for panel D: M, molecular size standards; 1, crude CLC prior to enzyme digestion (20 mg); 2, CLC
extract following enzyme digestion (20 mg); 3, purified CLC (20 mg). The Pro-Q Emerald stain of LPS (not shown here) looks similar to that of the
Western blot, and is shown in reference 29.
doi:10.1371/journal.pone.0019003.g002
Figure 3. Trimethylsilyl (TMS) ethers of the methyl glycosides from purified F. tularensis CLC. TMS derivatives of the glycoses from the
CLC were analyzed by GC/MS. All sugars and C18 fatty acids match in both retention time and mass spectrum with known standards.
doi:10.1371/journal.pone.0019003.g003
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promoter was identified upstream of FTL_1432, but not anywhere
else in the genetic sequence through FTL_1421. Furthermore,
overlapping primers were used to ‘‘walk’’ down the chromosome
from FTL_1432 through FTL_1421, and transcripts were
obtained for every two genes (data not shown) indicating the
genes in this locus are co-transcribed. Smith-Waterman analysis
indicated that FTL_1423 was most similar to a galactosyl
transferase from Streptococcus pneumoniae (34.5% amino acid
identity), and FTL_1422 was most similar (35.5% identity) to a
mannosyl transferase from Salmonella enterica. Additional evidence
that this locus contributed to CLC biosynthesis was obtained by
RT-qPCR (Fig. 4). The expression of FTL_1426, FTL_1424, and
FTL_1423 within the putative CLC carbohydrate locus was
significantly upregulated (P=0.025, 0.023, and 0.031, respectively)
up to three-fold when LVS was passed in CDMB and grown to
maximize CLC production (cultured on Glc-CDMA at 32uC for 5
days in 7% CO2) compared to growth under conditions that would
minimize CLC production (shaking at 200 rpm in brain heart
infusion broth supplemented with 0.1% L-cysteine hydrochloride
monohydrate) (BHIC) at 37uC to log phase).
Mutagenesis of FTL_1423/1422
FTL_1423 and FTL_1422 were deleted in LVS and
WbtIG191V_P17 by allelic exchange (see Materials and Methods).
Mutagenesis was confirmed by the inability to amplify either open
reading frame (ORF) by polymerase chain reaction (PCR), by
identification of the kanamycin resistance gene from the suicide
vector in the genome (by PCR and colony blot hybridization), and
by sequencing of PCR products (data not shown). Unlike LVS_P10
(Fig. 1A and 1E) and WbtIG191V_P17 (Fig. 1G), LVSD1423/
1422_P10 and WbtIG191V_P17D1423/1422 lacked any evidence of
a CLC following passage to enhance CLC synthesis (Fig. 1C and
1H, respectively). Furthermore, significantly less CLC carbohydrate
(P=0.01) and protein (P,0.01) was extracted from LVSD1423/
1422_P10 with 0.5%phenol than the parent (Fig. 5A), and 91% less
glucose, galactose, and mannose were present in extracts, as
determined by GC/MS (data not shown). Gel electrophoresis of the
CLC extracts from LVS_P10 and LVSD1423/1422_P10 con-
firmed the mutant was CLC-deficient (Fig. 5B). To confirm that
deletion of FTL_1423/1422 was solely responsible for the absence
of the CLC, both ORFs were cloned into expression vector
pFNLTP6 [39], which were then introduced into LVSD1423/1422
by electroporation. The complemented mutant (LVSD1423/
1422[1423/1422
+]_P10] (passed 10 times in CDMB) was restored
in CLC synthesis, as shown by electron microscopy (Fig. 1D), by
enhancement of the protein (partially) and carbohydrate content of
purified CLC (Fig. 5A), and by Stains All/silver stain following gel
electrophoresis (Fig. 5B).
To confirm that the deletion of FTL_1423 and FTL_1422 did not
have a polar effect on downstream genes, a DNA region from
FTL_1421 from the parent and the mutant was subjected to RT-
PCR (Fig. 6). The transcript of this region was identical to that of the
transcript from LVS, indicating that genes downstream of FTL_1423
and FTL_1422 were transcribed and not responsible for the loss of
CLC in mutant LVSD1423/1422. A separate control containing taq
polymerase and all other reagents except the reverse transcriptase
confirmed that the band was not genomic DNA (not shown).
In vitro growth rate and serum resistance of LVSD1423/
1422
The generation time for strain LVS in BHIC was approximately
2.5 h during log phase. However, mutant LVSD1423/1422 grew
substantially slower, with a generation time of approximately 6 h.
Both parent LVS and mutant LVSD1423/1422 were completely
resistant to the bactericidal action of up to 20% fresh guinea pig
serum and human serum (v/v), whereas there was 0% survival of
passed LVS O-antigen mutant WbtIG191V_P17 [11] in as little as
2% human serum (Fig. 7). Therefore, the CLC did not contribute
to serum resistance.
Viability of LVS, LVSD1423/1422, and LVSD1423/
1422[1423/1422
+] in macrophages
By 24 hours after inoculation, there was no obvious difference
in viability between LVS and LVSD1423/1422, but growth of
complemented strain LVSD1423/1422[1423/1422
+] was delayed
in J774A.1 cells assayed on separate days. However, the slopes for
intracellular growth of the bacteria as log10 CFU/well between 24
and 48 h for strains LVS, LVSD1423/1422, and LVSD1423/
1422[1423/1422
+] were similar (Fig. 8). Thus, the CLC did not
appear to be required for growth in murine macrophages.
Table 1. Putative genes and gene products that may contribute to F. tularensis CLC biosynthesis.
ORF in LVS ORF in Schu S4 Size (bp) Product
a
FTL_1432 FTT_0789 669 D-ribulose-phosphate 3-epimerase
FTL_1431 FTT_0790 1395 Sugar transferase family protein (Glycosyl transferase)
FTL_1430 FTT_0791 1020 UDP-glucose 4-epimerase
FTL_1429 FTT_0792 1230 Glycosyl transferase group 1 family protein
FTL_1428 FTT_0793 1683 ATP-binding membrane transporter
FTL_1427 FTT_0794 1287 Hypothetical protein (Phosphoserine phosphatase)
FTL_1426 FTT_0795 684 Hypothetical protein (protein cfa)
FTL_1425 FTT_0796 762 Hypothetical protein
FTL_1424 FTT_0797 960 Glycosyl transferase family protein (galactosyl transferase)
FTL_1423
b FTT_0798 1008 Glycosyl transferase family protein (galactosyl transferase)
FTL_1422
b FTT_0799 1014 Glycosyl transferase family protein (mannosyl transferase)
FTL-1421 FTT_0800 663 Haloacid dehalogenase
aDetermined by Smith-Waterman analysis
bDeletion of both of these genes resulted in CLC-deficient mutant LVSD1423/1422.
doi:10.1371/journal.pone.0019003.t001
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BALB/c mice were inoculated by the intranasal (IN) or IP
routes with LVS or LVSD1423/1422 to evaluate the effect of loss
of CLC on F. tularensis virulence (Fig. 9). All mice inoculated IN
with about 1.2610
4 CFU of LVS died or needed to be euthanized
in less than 10 days. In contrast, all mice inoculated IN with up to
1.6610
4 CFU of LVSD1423/1422 survived longer than six weeks
and never developed clinical symptoms (Fig. 9A).
All BALB/c mice inoculated IP with 41, 262 or 3,375 CFU of
LVS died within 7 days. In contrast, all mice inoculated IP with
1100 CFU or 2 of three mice inoculated IP with 11,136 CFU of
strain LVSD1423/1422 survived longer than four weeks. Howev-
er, all mice inoculated IP with 33,408 CFU of the mutant died or
were euthanized within 6 days (Fig. 9B). Although the lethal dose
of the mutant was lower following IP challenge than IN challenge,
the LD50 of the parent was also much lower following IP challenge
(,41 CFU) than IN challenge (,200 CFU).
Persistence of LVSD1423/1422 in mouse tissues
BALB/c mice were inoculated IN with 7.9610
3 CFU of LVS,
5.0610
4 CFU of LVSD1423/1422 (high dose), or 1.1610
4 CFU
of LVSD1423/1422 (low dose). The mice were euthanized at 2, 4,
or 7 days post-inoculation (PI), and the number of bacteria in the
lungs, liver, and spleen determined (Fig. 10). LVS numbers
increased in all three organs between day-2 and day-7 PI.
LVSD1423/1422 from the high dose challenge was recovered
from lungs (Fig. 10A) and liver (Fig. 10B) in approximately the
same numbers as LVS on day-2 and day-4 PI, but was recovered
in significantly fewer numbers from lungs, liver, and spleen on
day-7 PI (P,0.005 for each organ). Of interest was that from the
high dose challenge 1.5 logs more of the mutant than the parent
was recovered from the spleen at day 2 PI (Fig. 10C). This
difference may have been due to the dose of the mutant being 5
times higher than that of the parent, and the spleen concentrating
bacteria entering the blood stream. However, recovery of
LVSD1423/1422 from the spleen after low dose challenge (similar
to the LVS challenge dose) on day 2 PI was significantly lower.
While similar numbers of the mutant from low dose challenge
were present in the lungs at day 2 PI, recovery dropped off to
significantly fewer numbers by day 4 PI (P,0.05), and to a highly
Figure 5. CLC content from LVS_P10, LVSD1423/1422_P10, and LVSD1423/1422[1423/1422
+]_P10. Lanes: 1, LVS_P10; 2, LVSD1423/
1422_P10; 3, LVSD1423/1422[1423/1422
+]_P10. A) Carbohydrate and protein content of extracted CLC; B) Stains All/silver stain of extracted CLC. The
reducing carbohydrate content was measured by phenol sulfuric acid assay [47], and the protein content was measured by BCA assay. The CLC was
extracted from the same number of cells of each strain, as described in Materials and Methods.
doi:10.1371/journal.pone.0019003.g005
Figure 4. RT-qPCR of various regions of the putative CLC locus.
LVS was passed in defined medium and grown on defined medium agar
at 32uCi nC O 2 to maximize CLC content, or in defined medium broth at
37uC without preliminary passage to minimize CLC. The RNA was
isolated, converted to cDNA, and the cDNA amplified by quantitative
real-time PCR. The results are shown as the x-fold change in gene
expression using LVS grown in BHIC broth to log phase (minimal CLC
expression) as the calibrator and GAPDH as the endogenous control for
gene expression. The locus tag of each gene from LVS is shown on the
X-axis.
doi:10.1371/journal.pone.0019003.g004
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very few mutant bacteria from the low dose challenge were
recovered from the liver or spleen by day 2 PI, were present in
similar numbers as the parent in the liver by day 4 PI (significantly
fewer numbers in the spleen; P,0.05), and fewer numbers in the
liver and spleen (highly significant) by day 7 PI (P,0.005) (Fig. 10B
and 10C, respectively). These results indicated that following IN
challenge it took longer for similar numbers of the CLC mutant
(compared to the parent) to multiply and migrate from the lungs to
internal organs, could persist there for a few days, but unlike the
parent, began to be eliminated from the host. Thus, the expression
of the CLC was essential for full virulence of LVS in the
respiratory tract.
In a separate trial, C57BL/6 mice were inoculated with a
mixture of 5.9610
3 CFU/mouse of strain LVS mixed with
8.0610
3 CFU/mouse of mutant LVSD1423/1422. Five days PI
the mice were euthanized, tissue homogenates were cultured on
BHIC agar supplemented with 5% (v/v) sheep blood (BHICB),




were present per gram of liver, lungs, and spleen, respectively
(Table 2). The same tissue extracts plated on BHICB plates
containing kanamycin yielded 0, 0, and 6.1610
2 colonies per gram
of liver, lung, and spleen, respectively (Table 2). Therefore,
LVSD1423/1422 was significantly less fit (P,0.005 from each
organ) to survive in host tissues than LVS.
Protective efficacy of LVSD1423/1422 in mice
Mice inoculated once IN with 6.1610
3 CFU of LVSD1423/
1422 were challenged with 1.4610
5 CFU of LVS IN six weeks PI.
All mice survived challenge (Fig. 11) and none developed clinical
symptoms, whereas all control mice died or had to be euthanized
within 10 days. Thus, LVSD1423/1422 lacking CLC was capable
of inducing significant protection in BALB/c mice following IN
challenge with a high dose of LVS by 10 days post-challenge
(P,0.001). Mice previously inoculated IP with 39 CFU of
LVSD1423/1422 were challenged IN 7 weeks PI with
7.9610
3 CFU of LVS. The challenged mice developed mild
clinical symptoms (reduced activity) until about six days PI, after
which time they recovered (data not shown). Therefore, IP
inoculation with a low dose of 39 CFU/mouse also induced
protection against respiratory tularemia.
Discussion
F. tularensis has long been postulated to be encapsulated, based
primarily on electron microscopy [20,21,27]. However, the
electron dense material around F. tularensis is not always evident
Figure 6. RT-PCR of the DNA region FTL_1421 from LVSD1423/
1422. LVS and LVSD1423/1422 were grown on Glc-CDMA for at least 2
days, the RNA isolated, converted to cDNA, and amplified by PCR to
determine if a transcript from DNA downstream of the mutation was
made. Lanes: M, 1 kb+ DNA molecular size standards; 1, control
amplification of FTL_1425-1424 in LVS; 2, amplification of FTL_1425-
1424 upstream of the mutation in LVSD1423-1422; 3, control
amplification of FTL_1425-1424 upstream of the mutation (no bacteria);
4, control amplification of FTL_1421 from LVS; 5, amplification of
FTL_1421 immediately downstream of the mutation in LVSD1423/1422.
The presence of a normal band of about 351 bp from LVSD1423/1422
indicated that the mutation had no polar effect on downstream genes.
doi:10.1371/journal.pone.0019003.g006
Figure 7. Bactericidal assay of LVSD1423/1422 and control strains in the presence of fresh human serum. The bacteria were diluted in
PBS supplemented with 0.15 mM CaCl2, 0.5 mM MgCl2, and 2%, 4%, 8%, 16%, or 20% fresh, pooled human serum. Aliquots were cultured by viable
plate count before and after 60 min. incubation at 37uC. Bacterial strains: LVS,
_____N




Isolation and Mutagenesis of LVS CLC
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19003and has not been isolated, raising question as to whether a true
capsule actually exists. Cherwonogronzky et al. [27] showed that a
CLC can be enhanced by daily passage of F. tularensis LVS in
CDMB, followed by culture on CDMA, and that bacteria
enhanced for this surface material are more virulent in mice.
We confirmed by EM and by RT-qPCR that the CLC was
upregulated when LVS was passed in CDMB and grown at lower
temperature in CO2 for several days on CDMA, compared with
when the bacteria were grown shaking rapidly in complex broth
medium. A similar CLC could also be isolated and observed by
EM around type A strains SCHU S4 and TI0902. Three of four
ORFs within the putative CLC locus (FTL_1423/1424/1426)
were upregulated more than 2 to 3-fold when the bacteria were
grown to enhance CLC synthesis, but one ORF (FTL_1428) was
not. In data not shown FTL_1428 was also deleted by allelic
exchange, but no significant difference in phenotype or virulence
in mice could be identified between LVSD1428 and LVS. Smith-
Waterman analysis indicated that FTL_1428 has homology to a
family of ATP-binding cassette (ABC) transmembrane transport-
ers. Our hypothesis was that deletion of FTL_1428 may abolish
export of the CLC to the surface without inhibiting synthesis. As
this was not the case it is possible that FTL_1428 is not functional
or does not function in CLC export or regulation. Therefore, it
was not surprising that FTL_1428 was not upregulated during
enhanced CLC expression.
Analysis by GC/MS, chemical assays, amino acid analysis, and
electrophoretic analysis using the carbohydrate-specific fluorescent
stain Pro-Q Emerald indicated that unlike most bacterial capsules,
the predominant component of the CLC was protein, not
carbohydrate. Furthermore, following extraction with 0.5%
phenol, the CLC foamed and easily became insoluble. These are
also features of self-assembling bacterial surface (S)-layer proteins,
which are common in bacteria and are often glycosylated [40].
Proteinase K digestion was used to remove most of the protein to
improve solubility and focus on the carbohydrate component,
though some proteins were proteinase K resistant. Amino acid
analysis indicated that the majority of the amino acids remaining
after Proteinase K digestion were glutamic and aspartic acids
(unpublished data). Supplementation of the growth medium with
glucose further enhanced CLC synthesis, which is consistent with
the effect of glucose supplementation on cell surface carbohydrate
content [41]. Repeated analyses of the carbohydrate component of
the CLC consistently yielded glucose, galactose, and mannose.
Although the structure of the carbohydrate polymer has not yet
been determined, gel electrophoresis and column chromatography
confirmed that the material is of large molecular size. Bacterial
glycoproteins may have only 150 glycoses, but are attached as
heterogeneous repeating polymers, resulting in a ladder-like
banding pattern or smear in polyacrylamide gels [40]. A similar
ladder-like/smear profile was observed with the F. tularensis CLC
following staining with Stains All/silver stain and Western
blotting. Therefore, glucose, galactose, and mannose might
compose a trisaccharide polymer of a glycosylated protein.
Balonova et al. [42] have confirmed that glycosylated proteins
are present in F. tularensis. PilA and at least 14 additional proteins
were determined to be glycosylated by at least two methods.
Although the CLC may not have been upregulated in the bacteria
used in their studies, it is apparent that glycoproteins are common
in F. tularensis.
The CLC was distinct from the LPS, as determined by GC/
MS, lack of more LPS on cells enhanced for CLC, and the
molecular size of CLC isolated from an O-antigen mutant.
Apicella et al. [29] recently reported the presence of an O-antigen
capsule on F. tularensis, which was detected by monoclonal
antibody (MAb) binding. This MAb (11B7) bound to the crude
CLC initially extracted from the surface of LVS_P10, but not from
O-antigen mutant WbtIG191V_P17, or from the purified CLC
(unpublished data). Therefore, the O-antigen capsule is also
distinct from this CLC. ‘‘Unencapsulated’’ mutants of F. tularensis
LVS have been described that are highly susceptible to
complement-mediated killing [21,23]. However, these mutants
may also have been O-antigen deficient because F. tularensis LVS
lacking O-antigen and/or O-antigen capsule is highly serum-
sensitive [10,11,12,13,30]. In contrast, the CLC mutant generated
in this study was resistant to the bactericidal action of guinea pig or
human serum.
Loci that are responsible for the synthesis and export of
bacterial carbohydrate polymers are about 12–18 kb in size, and
contain genes that encode for ABC transporters, glycosyltransfer-
ases, membrane spanning proteins, etc. [43,44]. Larsson et al. [32]
described a putative polysaccharide locus from the genome
sequence of F. tularensis strain SCHU S4. To determine if this
Figure 8. Intracellular survival of F. tularensis LVSD1423/1422 in J774A.1 cells. The J774A.1 monolayer (approximately 4.5610
5
macrophages/well) was infected with approximately 5.5610
7 CFU/well of strain LVS (N), LVSD1423/1422 (m), or LVSD1423/1422[1423/1422
+]( X).
Intracellular survival of the bacteria was determined at 0, 24, 48, and 72 h post-infection, as described in Materials and Methods. Data are shown on
the log scale as the average number of bacteria recovered from dilutions of lysates of J774A.1 cells. The results shown were from two experiments
tested in duplicate at each time point. The slopes for intracellular growth of the bacteria as log10 CFU/well between the 24
th and the 48
th hour for
strains LVS, LVSD1423/1422, and LVSD1423/1422[1423/1422
+] were +1.44, +0.73, and +0.97, respectively.
doi:10.1371/journal.pone.0019003.g008
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FTL_1422 (which have homology to genes encoding for glycosyl
transferases) were mutated by allelic exchange. The deletion of
these genes appeared adequate to block assembly of the CLC on
the bacterial surface, as no CLC could be observed by EM around
LVSD1423/1422_P10, and little CLC could be isolated from this
mutant. Therefore, glycosylation of protein may be required for
formation of the CLC on the surface. Complementation of
LVSD1423/1422 in trans with both genes restored CLC
expression, and RT-PCR indicated that expression of the gene
downstream of the mutation was not affected, confirming that loss
of the CLC was not due to another mutation.
The capability of mutant LVSD1423/1422 to survive and grow
in the mouse macrophage-like cell line J774A.1 for 72 h PI was
similar to that of parent strain LVS. However, growth of the
complemented mutant in macrophages was delayed during the
first 24 h, after which time LVSD1423/1422[1423/1422
+] grew
at a similar rate as the parent and mutant. This growth lag may
have been due to catabolic effects and additional energy needed to
synthesize proteins by genes expressed on the plasmid in trans.
Nonetheless, the loss of CLC did not appear to substantially
interfere with intra-macrophage growth, in contrast to mutants
that fail to make LPS O-antigen or O-antigen capsule [30],
supporting the distinction between these surface structures.
Deletion of both FTL_1423 and FTL_1422 in LVS resulted in
significant loss of virulence in mice following IN challenge. These
results are consistent with those of Weiss et al. [45], who reported
that transposon mutagenesis of F. novicida FTN_1213 (equivalent
to FTL_1423 of LVS) resulted in moderate attenuation following
subcutaneous challenge of mice. The CLC mutant was also highly
attenuated following IP challenge. Inoculation with 11,136 CFU
of the mutant was required to cause skin ruffling and death of
some mice, which is a lower dose than that required for clinical
symptoms by the IN route. However, parent strain LVS is also
much more virulent for mice by the IP route than the intravenous
or subcutaneous routes [46]. Inoculation by the IP route
introduces the bacteria directly into the systemic tissues and
bypasses many of the innate immune defenses.
At 2 days and 4 days post-IN inoculation, the presence of
LVSD1423/1422 in the lungs, liver, and spleen was not highly
Figure 9. Survival of mice inoculated with F. tularensis LVSD1423/1422. Groups of BALB/c mice were inoculated IN (A) or IP (B), and survival
was monitored for six weeks. No mice challenged IN with LVSD1423/1422 died during the study. The doses and symbols used for IN inoculations
were about 1.2610
4 CFU/mouse of LVS (N), and about 1.6610
4 CFU of LVSD1423/1422 (m). The doses and symbols used for IP inoculations were
262 CFU/mouse of LVS (N); 3,375 CFU/mouse of LVS (x); 1,124 CFU/mouse of LVSD1423/1422 (m); 11,136 CFU/mouse of LVSD1423/1422 (¤);
33,408 CFU/mouse of LVSD1423/1422 (&).
doi:10.1371/journal.pone.0019003.g009
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challenge. However, the numbers of this mutant in all three organs
dropped significantly by 7 days PI, even after high dose
inoculation. However, it took significantly longer for bacteria from
the low dose challenge to migrate to the liver and spleen from the
lungs before growing to similar numbers as the parent, and then
began to be cleared. Thus, the CLC was necessary for F. tularensis
LVS to persist in the tissues. Furthermore, when LVS and
LVSD1423/1422 were inoculated concurrently into mice, the
mutant was unable to compete with the parent and few mutant
cells could be recovered from mouse tissues.
After a single IN inoculation with a high dose of LVSD1423/
1422 (up to 806 the LVS LD50), mice challenged with LVS IN
with .700 times the LD50 developed no clinical symptoms of
tularemia. In addition, mice inoculated IP with LVSD1423/1422
were also protected against low dose IN challenge with LVS,
demonstrating that systemic immunity to this mutant was
adequate for protection in the respiratory tract. Therefore, the
generation of CLC mutants in type A strains is warranted to
determine if such mutants are adequately attenuated and capable
of inducing a protective immune response against type A strains.
These results showed that the CLC may be a glycoprotein that
is upregulated under particular growth conditions, the glycose
component of the CLC contained glucose, galactose, and
mannose, the loci identified as FTL_1432 through FTL_1421 in
LVS contribute to CLC synthesis, and that the CLC is required
for full virulence of LVS, but not for inducing protective immunity
in mice against LVS.
Figure 10. Recovery of F. tularensis LVSD1423/1422 from the
tissues of mice following IN inoculation. Groups of BALB/c mice
were inoculated IN with 7.9610
3 CFUof strain LVS, 5.0610
4 CFU of strain
LVSD1423/1422 (high dose of mutant), or 1.1610
4 CFU of strain
LVSD1423/1422 (low dose of mutant). At 2, 4, or 7 days PI, mice were
euthanized. The lungs (A), liver (B), and spleen (C) were aseptically
removed, homogenized in PBS, and the CFU/g of tissue determined. The
recovery of bacteria from inoculated mice are shown as dark-filled bars
(LVS), open bars (high dose of LVSD1423/1422), and grey-filled bars (low
dose of LVSD1423/1422). The mean values of the CFUs of each dose of
the mutant were separately compared with LVS. The P values for the
differences between the mean values were ,0.05 (*) or ,0.005 (*).
doi:10.1371/journal.pone.0019003.g010
Table 2. Recovery of LVS and LVSD1423/1422 following
co-inoculation into C57BL/6 mice
a.
Organ CFU on BHICB










aFive mice were inoculated IN with a mixture of 5.9610
3 CFU of LVS and
8.0610
3 CFU of LVSD1423/1422. Five days PI the mice were euthanized, and
tissue extracts were cultured on BHICB with or without Kan. The numbers
shown represent the average CFU/g tissue.
bA few colonies were isolated from the lungs of one of five mice.
doi:10.1371/journal.pone.0019003.t002
Figure 11. Protective efficacy of LVSD1423/1422 against IN
challenge of mice with LVS. Groups of BALB/c mice were injected
with PBS (N), or inoculated with 6.1610
3 CFU/mouse of LVS D1423/
1422 (m). Six weeks PI, the mice were challenged IN with 1.4610
5 CFU/
mouse of LVS, and the mice were monitored for 4 weeks. No mice died
or were symptomatic by 10 days post-challenge. The P value for animal
survival after 10 days post-challenge was ,0.001.
doi:10.1371/journal.pone.0019003.g011
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Ethics statement
All proposals involving the use of living vertebrates are reviewed
by the Virginia Tech Institutional Animal Care and Use
Committee to assure humane care and treatment of the animals
involved. Approved proposals comply with "U.S. Government
Principles for the Utilization and Care of Vertebrate Animals
Used in Testing, Research, and Training, The Animal Welfare
Act, As Amended, The Public Health Service (PHS) Policy on
Humane Care and Use of Laboratory Animals, "Virginia Tech
Policies Governing the Use of Animals in Research and
Teaching". Virginia Tech has a written, approved Animal Welfare
Assurance on file with the PHS Office of Laboratory Animal
Welfare (OLAW). The university’s Animal Welfare Assurance
number is A-3208-01, expiration date 3-31-2012. All experiments
with animals were approved by the Virginia Tech Institutional
Animal Care and Use Committee under approved protocol 08-
257-CVM.
Bacterial strains and growth conditions
The bacterial strains used and their sources are listed in Table
S1. Escherichia coli DH5a was grown in Luria–Bertani (LB) medium
(Becton-Dickinson, Franklin Lakes, NJ) at 37uC containing 100 mg
ampicillin (Amp)/ml or 50 mg kanamycin (Kan)/ml for selection of
recombinant strains. F. tularensis strains were cultured from frozen
stock suspensions onto BHIC agar (Becton-Dickinson and Sigma-
Aldrich, St. Louis, MO) or BHICB, and incubated at 37uCi n7 %
CO2, unless otherwise stated. For culture in broth, F. tularensis
strains were grown with shaking (175 rpm) in BHIC broth at
37uC, or Glc-CDMB [27] at 32uC. For CLC preparation F.
tularensis LVS_P10 or WbtIG191V_P17 was grown on Glc-CDMA
in petri dishes (150 mm615 mm), and incubated at 32uCi n7 %
CO2 for 5 days. All experiments with LVS and mutants were
carried out in biosafety level (BSL)-2 facilities in an approved
biosafety cabinet.
Extraction of LPS
LPS was purified from F. tularensis LVS by aqueous phenol
extraction, enzyme digestion, and ultracentrifugation from killed
cells, as described previously [11].
Purification of CLC
The CLC was extracted from O-antigen LVS mutant WbtIG191V
that was passed daily 17 times in CDMB (WbtIG191v_P17) to avoid
contamination with LPS O-antigen. The cells were grown in Glc-
CDMB to mid-log phase, 500 ml was streaked onto large petri plates
of Glc-CDMA, and the plates were incubated for 5 days at 32uCi n
7% CO2. Approximately 10 g of bacterial cells (wet weight) were
gently resuspended into 200 ml of 0.5% phenol (in water) and
incubated at room temperature for 10 min. A thick, foamy extract
was obtained and subjected to centrifugation at 10,0006g for
15 min to remove cells, followed by centrifugation of the
supernatant again. The crude CLC was precipitated by addition
of 60 mM sodium acetate and 5 volumes of cold (220uC) ethanol,
and incubation at 220uC overnight. The precipitate was sediment-
ed by centrifugation at 10,0006g for 15 min and the pellet
suspended in 50 ml of 50 mM Trizma base (pH 7.3) containing
10 mM CaCl2, 10 mM MgCl2, and 0.05% sodium azide. Ten
microliters of RiboShredder RNase (Epicentre, Madison, WI) was
added, and the mixture incubated for 2 hours at 37uC. Twenty-five
mg/ml of DNase (Sigma-Aldrich, St. Louis, MO) was added and the
incubation continued for 1 hour. One hundred mg/ml of Proteinase
K (Sigma-Aldrich) was added and the mixture incubated for
2 hours at 37uC, followed by incubation at 55uC overnight.
Impurities were removed from the semi-purified complex by
ultracentrifugation at 100,0006g at 4uC for five hours to overnight.
The supernatant was dialyzed in a 50-kDa membrane against four
changes of distilled water and lyophilized. In some cases the CLC
was further purified by S-300 column chromatography with water
or 0.1% sodium dodecyl sulfate as eluent (15 mm6252 mm; GE
Healthcare Life Sciences, Piscataway, NJ), and the carbohydrate-
positive fractions were dialyzed and lyophilized.
CLC compositional analysis
CLC samples were extracted from the same number of cells, as
determined by optical density and viable plate count, and analyzed
by phenol-sulfuric acid assay [47] for carbohydrate content, KDO
assay [48] and Western blotting [11] for LPS, bicinchoninic acid
assay (BCA) for protein content (Pierce), and galactose oxidase
assay for galactose (Invitrogen). Glycosyl composition was
determined by combined GC/MS of the per-O-trimethylsilyl
(TMS) derivatives of the monosaccharide methyl glycosides
produced from the sample by acidic methanolysis, as described
[49].
Electrophoretic analysis and Western blotting
The electrophoretic profile of the CLC was resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis using NovexH
4–12% Pre-Cast bis-Tris gels (Invitrogen, Carlsbad, CA).
Following electrophoresis, the gel was fixed in 25% isopropanol/
10% acetic acid overnight and stained with 0.25% Stains All
(Sigma-Aldrich, St. Louis, MO) for 2 hours [50]. The bands were
visualized on a lightbox, color and size noted, and the gel silver
stained as described [50]. Separate gels were stained with
Coomassie Blue (Pierce, Rockford, IL), or the samples were
transferred to nitrocellulose using an X-Cell II Blot Module Semi-
Dry Transfer unit (Invitrogen) for Western blotting. Blots were
developed using rabbit polyclonal antiserum to LVS (1:10,400
dilution) [51], followed by anti-rabbit IgG coupled to horseradish
peroxidase (HRP; Jackson ImmunoResearch Labs) (1:2,000
dilution), and developed with 3,3,5,5-tetramethylbenzidine
(TMB; Pierce). The presence of carbohydrate in the gel was also
examined by staining with Pro-Q Emerald 300 (Molecular Probes,
Eugene, OR).
Negative stain electron microscopy
All F. tularensis strains were passed in CDMB to enhance CLC as
described for WbtIG191V_P17. F. tularensis strains were grown on
Glc-CDMA for 5 days at 32uC. The cells were gently scraped into
sodium cacodylate buffer containing 3% glutaraldehyde and
turned end-over-end for 2 hours. The cells were washed,
suspended in 10 mM sodium cacodylate buffer, adhered to
formvar-coated grids, stained with 0.5% uranyl acetate, and
viewed with a JEOL 100 CX-II transmission electron microscope
[52].
DNA sequence analyses
Annotation of putative F. tularensis LVS genes was determined
using BLAST [53] and the Smith-Waterman algorithm [54].
DNA manipulation
DNA extraction and manipulation procedures were carried out
as described [55]. Restriction enzymes and T4 DNA ligase were
obtained from New England BioLabs (Ipswich, MA). Plasmid
DNA was extracted using the QIAprep
H Spin Miniprep and
QIAquick
H Gel, as described by the manufacturer (QIAGEN,
Isolation and Mutagenesis of LVS CLC
PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e19003Valencia, CA). Genomic DNA from F. tularensis LVS was purified
using the PUREGENE
TM DNA Isolation Kit (Gentra Systems,
Minneapolis, MN). The StrataClone
TM PCR cloning kit (Strata-
gene
TM, La Jolla, CA) was used for PCR cloning. Oligonucleotides
were obtained from Integrated DNA Technologies, Inc., Coral-
ville, IA.
Construction of F. tularensis LVS allelic exchange mutants
Open reading frames FTL_1423 and FTL_1422 of strains LVS
and WbtIG191V_P17 were deleted by allelic exchange. A 1.3-kb
region upstream of FTL_1423 was amplified by PCR using the
primer pair (containing restriction enzyme sites) FTL1424_F_SalI
and FTL1423_R_StuI. A similar size region downstream of
FTL_1422 was separately amplified by PCR using the primer pair
FTL1422_F_StuI and FTL1421_R (Table S2). The two PCR
products were ligated to each other by fusion PCR using Taq
polymerase, and then cloned into TA cloning vector pSC-A
(Stratagene) to produce pSC-1423/1422. This plasmid was
isolated from E. coli DH5a grown on LB agar containing
100 mg/ml of Amp. The Tn903 npt gene [56] that confers Kan
resistance (Kan
r) was isolated from pUC4K by digestion with
PvuII, and cloned into StuI-digested (and blunt ended) plasmid
pSC-1423/1422, which resulted in the Kan
r gene being inserted
between FTL_1423 and FTL_1422. The resulting plasmid was
isolated from E. coli DH5a grown on LB agar containing 100 mg/
ml Kan, designated pSC-1423/1422K, and transformed into F.
tularensis LVS or WbtIG191V_P17 by cryotransformation [57].
Colonies were collected from the plates and subcultured on
BHICB containing 8 mg/ml of Kan for 6 days at 37uCi n5 %
CO2. Deletion of FTL_1423 and FTL_1422 and the presence of
the Kan
r gene from selected Kan
r colonies were determined by
PCR. Confirmation of the deletion was done by sequencing of the
region from FTL_1424 to FTL_1421 at the Virginia Bioinfor-
matics Institute core sequencing facility at Virginia Tech. One
verified recombinant of each strain was selected and designated
LVSD1423/1422 (derived from LVS) and WbtIG191V_P17D1423/
1422 (derived from O-antigen mutant WbtIG191V_P17). The capB
gene from these mutants was amplified by PCR, confirming they
were F. tularensis (data not shown).
For complementation, the entire FTL_1423-FTL_1422 region
was amplified by PCR and cloned into expression vector
pFNLTP6 [39] to produce pFTAB-1. FTL_1423/1422 was
transcribed under the groE promoter of pFNLTP6. The cat gene
encoding resistance to chloramphenicol and transcribed under
control of its native promoter was amplified by PCR from plasmid
pBBR1MCS [58] and cloned into the PstI site of pFTAB-1 to
produce pFTAB-2. This plasmid was introduced into LVSD1423/
1422 by cryotransformation [57]. Colonies resistant to 10 mg/ml
of chloramphenicol were subcultured, and a clone containing the
recombinant plasmid (determined by restriction enzyme digestion)
was designated LVSD1423/1422[1423/1422
+].
Reverse-transcriptase polymerase chain reaction (RT-PCR)
and reverse-transcriptase quantitative PCR (RT-qPCR)
RNA was isolated from F. tularensis LVS strains using the
RNeasy extraction kit following digestion of cells with 400 mg/ml
of lysozyme, as described (Qiagen, Valencia, CA). RNA integrity
values of 9.2–9.8 were obtained using the BioAnalyzer (Agilent,
Santa Clara, CA). For RT-PCR, bacteria were grown on Glc-
CDMA at 37uC for at least 2 days prior to extraction of RNA.
RNA was converted to cDNA and amplified with the SuperScript
III First Strand Synthesis System (Invitrogen, Carlsbad, CA) using
the corresponding primers listed in Table S3.
For RT-qPCR, bacteria were cultured on Glc-CDMA at 32uCi n
7% CO2 for 5 days or cultured in BHIC broth at 37uC with shaking
overnight to enhance or minimize CLC production, respectively.
RNA was converted to cDNA using the random priming method of
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems-AB, Foster City, CA). Real-time PCR reactions were
performed in 25 ml reactions using Power Sybr Green (Applied
Biosystems) and gene-specific primers (Table S3). RT-qPCR
reactions were carried out in a 7300 Real-Time PCR System and
analyzed using the SDS Software package (Applied Biosystems)
usingBHICbroth-grownLVSshakingat37uCasthe calibratorand
GAPDH as the endogenous control for gene expression. Biological
and technical replicates were done in triplicate.
Serum bactericidal assay
The bactericidal activity of 20% fresh guinea pig serum or
various dilutions of human serum for F. tularensis mutants was
determined as previously described [59]. Controls included LVS
and LVS O-antigen mutant WbtIG191V [11], exposed to 20% fresh
serum or 20% heat-inactivated serum.
Survival of F. tularensis LVS and mutants in
macrophages
The intracellular survival and growth of LVS, LVSD1423/
1422, and LVSD1423/1422[1423/1422
+] was determined in the
murine macrophage-like cell line J774A.1 (American Type
Culture Collection, Manassas, VA) by modification of published
methods [60]. The bacteria were mixed with macrophages at a
multiplicity of infection of 100:1 (bacteria:macrophages). After 1 h
incubation at 37uCi n5 %C O 2, extracellular bacteria were
removed by washing the cells with PBS, and the medium was
replaced with 1 ml of complete Dulbeccos’s Modified Eagle
Medium (DMEM) containing 50 mg/ml of gentamicin. After
45 min incubation, the cells were washed three times with PBS,
followed by the addition of complete DMEM without antibiotics.
The cells were then incubated at 37uCi n5 %C O 2 for 72 h. At 0,
24, 48, and 72 h PI, the J774A.1 cells were washed in PBS, lysed
by exposure to water for 5 min, and serial dilutions of the lysate
were cultured onto BHICB agar to determine the number of
viable intracellular bacteria. Because the assays were done on
different days and involved slightly different numbers of bacteria
and macrophages, the slope and standard deviation of bacterial
survival for each 24-h time period was calculated.
Virulence of F. tularensis LVS mutants in mice
Groups of five C57BL/6 mice (Charles River Laboratories,
Wilmington, MA) were inoculated by the intranasal (IN) route
with a mixture of 5.9610
3 CFU/mouse of LVS and
8.0610
3 CFU/mouse of LVSD1423/1422. All doses were con-
firmed by viable plate count on BHICB agar. Five days PI, the
mice were humanely euthanized with excess carbon dioxide, and
the liver, lungs, and spleen were harvested and cultured onto
BHICB with or without 8 mg/ml of kanamycin, and incubated at
37uCi n5 %C O 2 for up to 6 days.
In a separate trial, groups of six-week-old female BALB/c mice
(Charles River Laboratories, Wilmington, MA) were inoculated
with parent LVS or mutant LVSD1423/1422 IN or IP, and
survival was monitored for six weeks. The doses used for IN
inoculations were about 1.2610
4 CFU/mouse of LVS or about
1.6610
4 CFU of LVSD1423/1422. The doses used in IP
inoculations for LVS were 41, 262, or 3,375 CFU/mouse, or
1,124, 11,136, and 33,408 CFU of LVSD1423/1422. Challenge
experiments were done on three different days.
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7.9610
3 CFU of strain LVS, 5.0610
4 CFU of strain LVSD1423/
1422 (high dose), or 1.1610
4 CFU (low dose) of LVSD1423/1422.
At 2, 4, or 7 days PI, surviving mice were humanely euthanized
and the bacteria were cultured from the liver, lungs, and spleen as
described above.
Protective efficacy of F. tularensis LVS mutants in mice
BALB/c mice that survived and were healthy for six to seven
weeks following IN or IP inoculation with mutant LVSD1423/
1422 were challenged with 1.4610
5 CFU or 7.9610
3 CFU,
respectively, of LVS IN, and mortality and clinical symptoms
were recorded. Four weeks after challenge, surviving mice were
humanely euthanized using excess carbon dioxide, and portions of
the liver, lungs, and spleen were homogenized and cultured for F.
tularensis. Following challenge mice were monitored at predeter-
mined intervals and euthanized if they became moribund.
Statistical analyses
The Student t test [61] was used to evaluate the significance in
CLC compositional differences between LVS and mutant
LVSD1423/1422. ANOVA was used for the comparative
persistence of F. tularensis strains in liver, lungs, and spleen of
mice. The chi-squared test with larger contingency tables was used
to analyze the protective efficacy of the mutant in mice [61]. For
RT-qPCR the Ct of each replicate was used in an unpaired t test
between samples obtained from bacteria grown to enhance CLC
(grown on Glc-CDMA at 32uC), or minimize CLC expression
(grown in BHIC broth at 37uC). Statistical analyses and P values
were calculated using InStat software (GraphPad, La Jolla, CA).
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